What should myeloma patients know about bispecific antibodies? Published 2022-08-18 Download video MP4 360p Recommendations 22:21 TECVAYLI (Teclistamab) Everything You Need to Know 07:19 What is Immunotherapy for Multiple Myeloma? Understanding Its Role in Treatment 14:22 Medical Stories - Multiple Myeloma: Kenny's Story 03:57 What should care providers of myeloma patients know about CAR T-cell therapy? 05:54 Why is 17p deletion (17p-) considered to be a poor prognostic factor for myeloma patients? 04:01 What are the differences between CAR T-cell therapy and bispecific antibodies? 20:51 Myeloma Patients are Having LONGER Remissions with this Game Changing Treatment! | The Patient Story 23:13 Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute 47:00 Common symptoms and presentations of Multiple Myeloma to primary care physicians 00:55 What are Bispecific Antibodies? 04:14 Challenges with the real-world use of CAR-T therapy in multiple myeloma 32:46 Erin's Multiple Myeloma Story: From Back Pain to a Stage 3 Diagnosis | The Patient Story 28:40 All About TALVEY (talquetamab) 05:39 Myeloma UK's Early Diagnosis Programme 1:03:49 A 2023 Update on CAR-T Therapy in Myeloma with Dr. Craig Hofmeister 10:22 150 MINUTA - Od multiplog mijeloma u Srbiji godišnje oboli 339 osoba | PRVA 06:09 Bispecific Antibodies | High Impact Topic (HIT) 03:44 What should myeloma patients know about talquetamab? 05:44 Bispecific Antibodies: Early Side Effects 12:19 Vit D research, definitive and significant Similar videos 05:58 What Myeloma Patients Need to Know About Bispecific Antibodies 05:08 What should myeloma patients know about the new immune therapies? 57:20 Know Your Myeloma Immunotherapy: Bispecific Antibodies with Dr. Cesar Rodriguez 11:58 What should patients know about bispecific antibody therapy and the risk for infection? 04:45 Bispecifics Part 2: Monoclonal and Bispecific Antibodies 25:45 Care Partners | What Should You Know About the Bispecific Antibody Treatment for Myeloma? 06:35 The benefits of bispecific antibodies for treating multiple myeloma 01:47 LINKER-MM1: linvoseltamab, a bispecific antibody, in R/R multiple myeloma 07:06 Efficacy and safety of elranatamab BCMA-CD3 bispecific antibody, in patients with RRMM 30:24 FAQs on BMCA-Targeted Bispecific Antibodies in Multiple Myeloma 28:40 Bispecific Antibody Therapy in Multiple Myeloma 03:28 The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myeloma More results